{"id":"W2559341198","doi":"10.1007/s00277-016-2878-5","title":"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","year":2016,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Pharmacyclics; Genentech; H. Lundbeck A/S; Baxalta; Celgene; Gilead Sciences; Servier; Astellas Pharma; TG Therapeutics; Amgen; Pfizer; F. Hoffmann-La Roche; Roche","keywords":"Medicine; Bendamustine; Rituximab; Obinutuzumab; Internal medicine; Follicular lymphoma; Quality of life (healthcare); Lymphoma; Refractory (planetary science); Oncology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005759519,0.0003664383,0.001911554,0.0003443123,0.00005105353,0.000005052995,0.0001451722,0.0001445244,0.00002824752],"category_scores_gemma":[0.000176591,0.0001860579,0.00007033676,0.0004634754,0.0003175095,0.00009471503,0.00006015955,0.0001132688,0.000002559411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00017675,"about_ca_system_score_gemma":0.0005112432,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005718681,"about_ca_topic_score_gemma":0.00212592,"domain_scores_codex":[0.9967305,0.0004300255,0.001370089,0.0005086376,0.000469849,0.0004909181],"domain_scores_gemma":[0.997534,0.0006874792,0.0008205674,0.0005525367,0.0002143292,0.0001910424],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05538351,0.02141991,0.9079871,0.0002140565,0.0006772624,0.0002069428,0.002347395,0.000005367783,0.00002025038,0.0001089021,0.0001040803,0.01152521],"study_design_scores_gemma":[0.2241158,0.02245381,0.7513846,0.0005430126,0.00009859651,0.00003234396,0.000675963,0.00001592896,0.0005039546,0.000005189496,0.00001056537,0.000160292],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952338,0.001060655,0.000003277278,0.001624999,0.00004123219,0.00188013,0.00008406737,0.00001918016,0.00005265538],"genre_scores_gemma":[0.9993622,0.0001111766,0.00003498215,0.0002326943,0.0000101408,0.0001326216,0.00008365003,0.00002715599,0.00000538412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1687323,"threshold_uncertainty_score":0.8644974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0440020925305904,"score_gpt":0.3413790804974494,"score_spread":0.297376987966859,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}